2nd Quarter - Report

INOVIO PHARMACEUTICALS, INC. for INOVIO PHARMACEUTICALS, INC.

Firm
Client
Income
—
Expenses
$140,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Issues related to COVID-19 research and development, vaccine distribution and manufacturing; Issues related to Oncology; Next Generation COVID-19 vaccines and boosters; Medicare Part B and HPV; Issues related to BARDA/ASPR and manufacturing of COVID-19 vaccines and boosters; Prescription Drug User Fee Act (PDUFA); Medical Device User Fees Amendment (MDUFA IV); ARPA-H Act, H.R 5585; Accelerated Approval Integrity Act of 2022, H.R. 6963; Speeding Therapy Access Today (STAT) Act, H.R. 1730; Prevent Pandemic Act, S. 3799

LobbyistCovered position, as disclosed
COOKAB HASHEMI —

Contacted: White House Office; Defense, Dept of (DOD); Health & Human Services, Dept of (HHS); State, Dept of (DOS); SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 1730 (117th), H.R. 6963 (117th), H.R. 5585 (117th), S. 3799 (117th)

Budget/Appropriations BUD

FY 2023 appropriations - LHHS, AG/FDA, State, Foreign Ops

LobbyistCovered position, as disclosed
COOKAB HASHEMI —

Contacted: HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.